Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Why Is Imagion Biosystems Ltd (ASX: IBX) Share Price Under Pressure Today?

• The company continues advancing the clinical development of its MagSense® imaging platform.

Aditi Sarkar | 02 July 2026

EchoIQ (ASX: EIQ) Gains as AI Heart Screening Company Draws Interest

• AI heart screening: The company uses artificial intelligence to help detect structural heart disease from echocardiogram data.

Aditi Sarkar | 02 July 2026

EBR Systems (ASX: EBR) Advances as Heart Failure Device Maker Gains Ground

• Medtech mover: EBR Systems gained roughly 13 percent, adding healthcare exposure to the gainers list.

Aditi Sarkar | 02 July 2026

Imricor Medical Systems (ASX: IMR) Rises as MRI-Guided Ablation Firm Gains

• MRI-guided ablation: The company builds devices for cardiac ablation performed inside an MRI scanner.

Aditi Sarkar | 02 July 2026

Imricor Medical Systems (ASX:IMR) Advances U.S. Commercialisation Strategy with FDA Pediatric Clearances

• Imricor Medical Systems shares rose 11.91% to AUD 2.02 during the afternoon session on 2 July 2026.

Aditi Sarkar | 02 July 2026

Algorae Pharmaceuticals (ASX:1AI) Clarifies Revenue Pathway Under NSW Health Supply Arrangement

• Algorae Pharmaceuticals provided a supplementary announcement clarifying details of its NSW Health public hospital supply arrangement.

Aditi Sarkar | 02 July 2026

BCAL Diagnostics (ASX:BDX) Expands Diagnostics Strategy with New Investment

• The company will acquire a 10.2% stake in Genetic Signatures Ltd for AUD 1.39 million.

Aditi Sarkar | 02 July 2026

OncoSil Medical (ASX:OSL) Advances European Clinical Strategy Through PALACROS

• OncoSil Medical shares rose 0.66% to AUD 0.76 on 2 July 2026 after a favourable European clinical research update.

Aditi Sarkar | 02 July 2026

Starpharma Holdings (ASX:SPL) Shares Climb as Radiopharmaceutical Program Gains Momentum

• Starpharma shares rose 4.23% to AUD 0.74 during the morning session on 2 July 2026 after two favourable DEP radiopharmaceutical updates.

Aditi Sarkar | 02 July 2026

Cyclopharm (ASX:CYC) Gains as Record Revenue Offsets US Guidance Delay

• The company expects 1H FY26 global revenue of approximately AUD 17.1 million, up around 11% year-on-year.

Aditi Sarkar | 02 July 2026
Support

Hi! How can we help you today?

Loading…